Business Description
Neovacs SA
NAICS : 325412
SIC : 2834
ISIN : FR001400MV37
Compare
Compare
Traded in other countries / regions
ALNEV.France0LW0.Germany0W8U.UK IPO Date
2011-05-24Description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.89 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.84 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -2.33 | |||||
| Beneish M-Score | 0.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 99.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.08 | |||||
| 9-Day RSI | 15.23 | |||||
| 14-Day RSI | 19.02 | |||||
| 6-1 Month Momentum % | -73.33 | |||||
| 12-1 Month Momentum % | -100 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.91 | |||||
| Quick Ratio | 1.91 | |||||
| Cash Ratio | 1.39 | |||||
| Days Sales Outstanding | 456.82 | |||||
| Days Payable | 1347.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1131.73 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -924.53 | |||||
| Operating Margin % | -12860.38 | |||||
| Net Margin % | -9428.3 | |||||
| FCF Margin % | -9296.23 | |||||
| ROE % | -10.27 | |||||
| ROA % | -9.17 | |||||
| ROIC % | -15.86 | |||||
| ROC (Joel Greenblatt) % | -1033.59 | |||||
| ROCE % | -10.46 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.01 | |||||
| EV-to-EBIT | 0.52 | |||||
| EV-to-EBITDA | 0.71 | |||||
| EV-to-Revenue | -52.97 | |||||
| EV-to-FCF | 0.56 | |||||
| Earnings Yield (Greenblatt) % | 190.12 | |||||
| FCF Yield % | -4284.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neovacs SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.053 | ||
| EPS (TTM) (€) | -268873.3 | ||
| Beta | 0 | ||
| Volatility % | 111.62 | ||
| 14-Day RSI | 19.02 | ||
| 14-Day ATR (€) | 0.093316 | ||
| 20-Day SMA (€) | 0.505835 | ||
| 12-1 Month Momentum % | -100 | ||
| 52-Week Range (€) | 0.29 - 32000 | ||
| Shares Outstanding (Mil) | 0.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neovacs SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neovacs SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neovacs SA Frequently Asked Questions
What is Neovacs SA(XPAR:ALNEV)'s stock price today?
The current price of XPAR:ALNEV is €0.29. The 52 week high of XPAR:ALNEV is €32000.00 and 52 week low is €0.29.
When is next earnings date of Neovacs SA(XPAR:ALNEV)?
The next earnings date of Neovacs SA(XPAR:ALNEV) is .
Does Neovacs SA(XPAR:ALNEV) pay dividends? If so, how much?
Neovacs SA(XPAR:ALNEV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers